NRX Pharma's KetaFree: FDA Accepts Application for First Preservative-Free IV Ketamine

FDA Milestone for KetaFree

• 💊 NRX Pharmaceuticals has achieved a significant regulatory milestone as the US FDA has accepted its Abbreviated New Drug Application (ANDA) for KetaFree.
• 💡 KetaFree is an investigational preservative-free intravenous ketamine formulation.

Potential for First-to-Market

• 🎯 If approved, KetaFree could become the first preservative-free IV ketamine product available in the United States.
• ⚠️ This addresses concerns regarding preservatives found in current standard ketamine vials, which NRX states the FDA does not recognize as safe.

Manufacturing and Timeline

• 🏭 NRX has already manufactured initial registration batches and possesses the capability to scale production to up to 1 million vials per month.
• 🗓️ The FDA has set a review goal date of July 29, 2026, with potential approval on or before this date if the review proceeds as scheduled.

Market Significance

• 📈 This development is crucial for patients and prescribers seeking safer ketamine treatment options.
• 🚀 It is also significant for investors monitoring the expanding markets for depression treatment and suicide prevention.